Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,12177688,time to reach the maximum plasma concentration (T(max)),The time to reach the maximum plasma concentration (T(max)) is 2.0 h for imidapril and 9.3 h for imidaprilat.,"Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,2.0,8600,DB01197,Captopril
,12177688,time to reach the maximum plasma concentration (T(max)),The time to reach the maximum plasma concentration (T(max)) is 2.0 h for imidapril and 9.3 h for imidaprilat.,"Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,9.3,8601,DB01197,Captopril
,12177688,elimination half-lives (t(1/2)),"The elimination half-lives (t(1/2)) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively.","Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,1.7,8602,DB01197,Captopril
,12177688,elimination half-lives (t(1/2)),"The elimination half-lives (t(1/2)) of imidapril and imidaprilat is 1.7 and 14.8 h, respectively.","Protection of the cardiovascular system by imidapril, a versatile angiotensin-converting enzyme inhibitor. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12177688/),h,14.8,8603,DB01197,Captopril
,2077146,half-life,"2) The blood concentration of captopril reached its peak in 2 h after medication, the mean value being 274 ng/ml and the half-life 3.16 h.",Effect of captopril on congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2077146/),h,3.16,12750,DB01197,Captopril
,3517077,maximum concentration (Cmax),"Mean values for the maximum concentration (Cmax) were 803 and 66.3 ng/mL for CAP and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[ng] / [ml],803,27361,DB01197,Captopril
,3517077,maximum concentration (Cmax),"Mean values for the maximum concentration (Cmax) were 803 and 66.3 ng/mL for CAP and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[ng] / [ml],66.3,27362,DB01197,Captopril
,3517077,time to maximum concentration (tmax),"Mean time to maximum concentration (tmax) was determined as 1.0, 1.4, and 1.0 for CAP, TOT, and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,1.0,27363,DB01197,Captopril
,3517077,time to maximum concentration (tmax),"Mean time to maximum concentration (tmax) was determined as 1.0, 1.4, and 1.0 for CAP, TOT, and Me-CAP, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,1.4,27364,DB01197,Captopril
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[hr-ng] / [ml],"1,394",27365,DB01197,Captopril
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),h,0-8,27366,DB01197,Captopril
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[hr-ng] / [ml],"17,316",27367,DB01197,Captopril
,3517077,areas under the plasma concentration-time curve (AUC),"Mean areas under the plasma concentration-time curve (AUC) were 1,394 hr-ng/mL (CAP, 0-8 hr) and 17,316 hr-ng/mL (TOT, 0-24 hr).",Pharmacokinetics of captopril in elderly healthy male volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),h,0-24,27368,DB01197,Captopril
,3517077,half-life (t 1/2),"The mean estimated half-life (t 1/2) for CAP was 1.4 hr, and its renal clearance was 187 mL/hr/kg.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),h,1.4,27369,DB01197,Captopril
,3517077,renal clearance,"The mean estimated half-life (t 1/2) for CAP was 1.4 hr, and its renal clearance was 187 mL/hr/kg.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),[ml] / [h·kg],187,27370,DB01197,Captopril
,3517077,urinary excretion,"Mean urinary excretion over 24 hr was 20.8 and 53.1 for CAP and TOT, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,20.8,27371,DB01197,Captopril
,3517077,urinary excretion,"Mean urinary excretion over 24 hr was 20.8 and 53.1 for CAP and TOT, respectively.",Pharmacokinetics of captopril in elderly healthy male volunteers. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3517077/),,53.1,27372,DB01197,Captopril
,3292102,body clearance,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [h·kg],0.7,28702,DB01197,Captopril
,3292102,steady-state volume of distribution,"In healthy subjects given captopril intravenously, the body clearance of captopril and steady-state volume of distribution were about 0.7 L/h/kg and 0.8 L/kg, respectively.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),[l] / [kg],0.8,28703,DB01197,Captopril
,3292102,elimination half-life,The elimination half-life of unchanged captopril was approximately 2 hours.,Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),h,2,28704,DB01197,Captopril
,3292102,bioavailability,"In healthy subjects, about 70 to 75% of an oral dose is absorbed and the bioavailability of captopril is approximately 65%.",Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3292102/),%,65,28705,DB01197,Captopril
,2527539,Di,6. Dialysis clearance was approximately 2 l h-1 for cilazapril and for cilazaprilat.,Pharmacokinetics of cilazapril in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2527539/),[l] / [h],2,28907,DB01197,Captopril
,6389377,peak captopril concentrations,"The peak captopril concentrations attained were 701 +/- 81 ng/ml (mean +/- s.e.m.) after fasting, 351 +/- 56 ng/ml with an antacid (p less than 0.05) and 140 +/- 14 ng/ml after a meal (p less than 0.01).",Impairment of captopril bioavailability by concomitant food and antacid intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),[ng] / [ml],701,38771,DB01197,Captopril
,6389377,peak captopril concentrations,"The peak captopril concentrations attained were 701 +/- 81 ng/ml (mean +/- s.e.m.) after fasting, 351 +/- 56 ng/ml with an antacid (p less than 0.05) and 140 +/- 14 ng/ml after a meal (p less than 0.01).",Impairment of captopril bioavailability by concomitant food and antacid intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),[ng] / [ml],351,38772,DB01197,Captopril
,6389377,peak captopril concentrations,"The peak captopril concentrations attained were 701 +/- 81 ng/ml (mean +/- s.e.m.) after fasting, 351 +/- 56 ng/ml with an antacid (p less than 0.05) and 140 +/- 14 ng/ml after a meal (p less than 0.01).",Impairment of captopril bioavailability by concomitant food and antacid intake. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),[ng] / [ml],140,38773,DB01197,Captopril
,6389377,areas under the blood concentration-time curves,"The peak concentrations were reached in 0.5, 0.9 and 1.5 h (p less than 0.01), and the areas under the blood concentration-time curves were 782 +/- 86, 456 +/- 60 (p less than 0.05) and 344 +/- 47 ng X h/ml (p less than 0.01), respectively.",Impairment of captopril bioavailability by concomitant food and antacid intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),[h·ng] / [ml],782,38774,DB01197,Captopril
,6389377,areas under the blood concentration-time curves,"The peak concentrations were reached in 0.5, 0.9 and 1.5 h (p less than 0.01), and the areas under the blood concentration-time curves were 782 +/- 86, 456 +/- 60 (p less than 0.05) and 344 +/- 47 ng X h/ml (p less than 0.01), respectively.",Impairment of captopril bioavailability by concomitant food and antacid intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),[h·ng] / [ml],456,38775,DB01197,Captopril
,6389377,areas under the blood concentration-time curves,"The peak concentrations were reached in 0.5, 0.9 and 1.5 h (p less than 0.01), and the areas under the blood concentration-time curves were 782 +/- 86, 456 +/- 60 (p less than 0.05) and 344 +/- 47 ng X h/ml (p less than 0.01), respectively.",Impairment of captopril bioavailability by concomitant food and antacid intake. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),[h·ng] / [ml],344,38776,DB01197,Captopril
,6389377,relative bioavailability,"The relative bioavailability of captopril was 0.66 and 0.48 with antacid and after food, respectively.",Impairment of captopril bioavailability by concomitant food and antacid intake. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),,0.66,38777,DB01197,Captopril
,6389377,relative bioavailability,"The relative bioavailability of captopril was 0.66 and 0.48 with antacid and after food, respectively.",Impairment of captopril bioavailability by concomitant food and antacid intake. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6389377/),,0.48,38778,DB01197,Captopril
,11084249,maximum plasma concentration,"In normotensive rabbits, the blood concentration versus time course of captopril after transdermal administration could be described well by a two-compartment model, and the maximum plasma concentration (5. 68+/-2.05 microg ml(-1)) was achieved in about 7 h.",Evaluation of pharmacokinetics and pharmacodynamics of captopril from transdermal hydrophilic gels in normotensive rabbits and spontaneously hypertensive rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084249/),[μg] / [ml],5. 68,40908,DB01197,Captopril
,11084249,concentration at half maximum effect (EC(50)),The maximum reduction in MBP (E(max)) was 36.23% and the concentration at half maximum effect (EC(50)) was 0.24 microg ml(-1).,Evaluation of pharmacokinetics and pharmacodynamics of captopril from transdermal hydrophilic gels in normotensive rabbits and spontaneously hypertensive rats. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11084249/),[μg] / [ml],0.24,40909,DB01197,Captopril
,2484083,IC50,"In vitro, SQ 26,703 was more potent than captopril as an inhibitor of rabbit lung ACE (IC50 = 8 vs. 23 nM).","Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484083/),nM,8,41752,DB01197,Captopril
,2484083,IC50,"In vitro, SQ 26,703 was more potent than captopril as an inhibitor of rabbit lung ACE (IC50 = 8 vs. 23 nM).","Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484083/),nM,23,41753,DB01197,Captopril
,2484083,EC50,"SQ 26,703 was also a potent inhibitor of angiotensin I (AI)-induced contractions (EC50 = 3 nM) and a potentiator of bradykinin-induced contractions (EC50 = 1 nM) of isolated guinea pig ileum, while it had no effect on the inotropic effects of angiotensin II, BaCl2, PGE1, histamine, serotonin, or acetycholine in the same tissue, signifying that zofenopril is a specific inhibitor of ACE.","Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484083/),nM,3,41754,DB01197,Captopril
,2484083,EC50,"SQ 26,703 was also a potent inhibitor of angiotensin I (AI)-induced contractions (EC50 = 3 nM) and a potentiator of bradykinin-induced contractions (EC50 = 1 nM) of isolated guinea pig ileum, while it had no effect on the inotropic effects of angiotensin II, BaCl2, PGE1, histamine, serotonin, or acetycholine in the same tissue, signifying that zofenopril is a specific inhibitor of ACE.","Preclinical pharmacology of zofenopril, an inhibitor of angiotensin I converting enzyme. ",EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2484083/),nM,1,41755,DB01197,Captopril
,2499471,clearance,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[ml] / [min],67.3,44373,DB01197,Captopril
,2499471,clearance,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[ml] / [min],47.5,44374,DB01197,Captopril
,2499471,proximal absolute reabsorption of fluid,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[ml] / [min],53.9 to 41.5,44375,DB01197,Captopril
,2499471,distal absolute reabsorption of sodium,"In RVH captopril reduced 51-Cr-EDTA clearance (67.3 (median) to 47.5 ml min-1, P less than 0.01), proximal absolute reabsorption of fluid (53.9 to 41.5 ml min-1, P less than 0.01) and distal absolute reabsorption of sodium (2195 to 1402 mumol min-1, P less than 0.01), whereas proximal fractional reabsorption increased slightly (77.5 to 80.2%, P less than 0.02).",Abnormal glomerular and tubular function during angiotensin converting enzyme inhibition in renovascular hypertension evaluated by the lithium clearance method. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2499471/),[μM] / [min],2195 to 1402,44376,DB01197,Captopril
,9696583,yield of,The average yield of derivatization of the unchanged captopril was 73.6% and the recovery of captopril-adduct reached 93.1%.,Captopril: determination in blood and pharmacokinetics after single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696583/),%,73.6,48200,DB01197,Captopril
,9696583,recovery,The average yield of derivatization of the unchanged captopril was 73.6% and the recovery of captopril-adduct reached 93.1%.,Captopril: determination in blood and pharmacokinetics after single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696583/),%,93.1,48201,DB01197,Captopril
,9696583,limit of detection,"The limit of detection was 15 ng ml-1, while the quantitative limit was 30 ng ml-1.",Captopril: determination in blood and pharmacokinetics after single oral dose. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9696583/),[ng] / [ml],15,48202,DB01197,Captopril
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,7.8,49430,DB01197,Captopril
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,7.0,49431,DB01197,Captopril
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,6.5,49432,DB01197,Captopril
,3034318,Elimination half-lives,Elimination half-lives of total captopril after acute (7.8 +/- 2.3 h) or chronic (7.0 +/- 0.5 h) captopril dosing were similar to those of HCTZ after acute (6.5 +/- 1.0 h) or chronic (8.0 +/- 2.5 h) HCTZ dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,8.0,49433,DB01197,Captopril
,3034318,Elimination half-life,Elimination half-life of free unchanged captopril was 0.81 +/- 0.09 h after acute and 0.96 +/- 0.03 h after chronic captopril dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,0.81,49434,DB01197,Captopril
,3034318,Elimination half-life,Elimination half-life of free unchanged captopril was 0.81 +/- 0.09 h after acute and 0.96 +/- 0.03 h after chronic captopril dosing.,Pharmacokinetics and biological effects of captopril and hydrochlorothiazide after acute and chronic administration either alone or in combination in hypertensive patients. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034318/),h,0.96,49435,DB01197,Captopril
,9931165,RPF,Administration of captopril at a dose of 25 mg during glucose infusion led to an increase in RPF of 173+/-24 mL.,Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931165/),,173,57916,DB01197,Captopril
,9931165,RPF,min-1. 1.73 m-2 (P<0.01) but did not significantly change RPF in the absence of hyperglycemia (7+/-21 mL. min-1. 1.73 m-2).,Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9931165/),[1.73·ml] / [(m)^2·min],7,57917,DB01197,Captopril
,7031222,Absorption,"Absorption of the total radioactivity in 2-month-old mice averaged 49 and 48%, respectively, of the 50- and 1350-mg/kg doses given in the diet and 57 and 65%, respectively, of the doses given by gavage.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,49,59061,DB01197,Captopril
,7031222,Absorption,"Absorption of the total radioactivity in 2-month-old mice averaged 49 and 48%, respectively, of the 50- and 1350-mg/kg doses given in the diet and 57 and 65%, respectively, of the doses given by gavage.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,48,59062,DB01197,Captopril
,7031222,Absorption,"Absorption of the total radioactivity in 2-month-old mice averaged 49 and 48%, respectively, of the 50- and 1350-mg/kg doses given in the diet and 57 and 65%, respectively, of the doses given by gavage.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,57,59063,DB01197,Captopril
,7031222,Absorption,"Absorption of the total radioactivity in 2-month-old mice averaged 49 and 48%, respectively, of the 50- and 1350-mg/kg doses given in the diet and 57 and 65%, respectively, of the doses given by gavage.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,65,59064,DB01197,Captopril
,7031222,bioavailability,"The bioavailability of I in 2-month-old mice averaged 48 and 39% (diet) and 44 and 59% (gavage) of the 50- and 1350-mg/kg doses, respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,48,59065,DB01197,Captopril
,7031222,bioavailability,"The bioavailability of I in 2-month-old mice averaged 48 and 39% (diet) and 44 and 59% (gavage) of the 50- and 1350-mg/kg doses, respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,39,59066,DB01197,Captopril
,7031222,bioavailability,"The bioavailability of I in 2-month-old mice averaged 48 and 39% (diet) and 44 and 59% (gavage) of the 50- and 1350-mg/kg doses, respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,44,59067,DB01197,Captopril
,7031222,bioavailability,"The bioavailability of I in 2-month-old mice averaged 48 and 39% (diet) and 44 and 59% (gavage) of the 50- and 1350-mg/kg doses, respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,59,59068,DB01197,Captopril
,7031222,minimum absorption,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,36,59069,DB01197,Captopril
,7031222,minimum absorption,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,45,59070,DB01197,Captopril
,7031222,minimum absorption,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,51,59071,DB01197,Captopril
,7031222,minimum absorption,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,71,59072,DB01197,Captopril
,7031222,minimum bioavailability,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,20,59073,DB01197,Captopril
,7031222,minimum bioavailability,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,29,59074,DB01197,Captopril
,7031222,minimum bioavailability,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,39,59075,DB01197,Captopril
,7031222,minimum bioavailability,"In 2- and 15-month-old rats, minimum absorption of the 1350-mg/kg dose averaged 36 and 45% (diet) and 51 and 71% (gavage), respectively; the minimum bioavailability averaged 20 and 29% (diet) and 39 and 44% (gavage), respectively.",Absorption and bioavailability of captopril in mice and rats after administration by gavage and in the diet. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7031222/),%,44,59076,DB01197,Captopril
,7589027,maximum concentration (Cmax,"The sauna significantly increased the maximum concentration (Cmax 41 vs. 28 ng.ml-1) of propranolol and the mean plasma propranolol concentration 60 and 90 min, and 2 and 3 h after drug administration.",Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),[ng] / [ml],41,63008,DB01197,Captopril
,7589027,maximum concentration (Cmax,"The sauna significantly increased the maximum concentration (Cmax 41 vs. 28 ng.ml-1) of propranolol and the mean plasma propranolol concentration 60 and 90 min, and 2 and 3 h after drug administration.",Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),[ng] / [ml],28,63009,DB01197,Captopril
,7589027,AUC0-5h,It also significantly increased the AUC0-5h (119 vs 71 micrograms.,Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),μg,119,63010,DB01197,Captopril
,7589027,AUC0-5h,It also significantly increased the AUC0-5h (119 vs 71 micrograms.,Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7589027/),μg,71,63011,DB01197,Captopril
,7019414,sensitivity,The sensitivity of the assay was 150 pmoles/ml.,High-performance liquid chromatographic analysis of captopril in plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7019414/),[pmoles] / [ml],150,72100,DB01197,Captopril
,7019414,terminal half-life,"Thereafter, the plasma levels declined rapidly, and the terminal half-life was approximately 40 min.",High-performance liquid chromatographic analysis of captopril in plasma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7019414/),min,40,72101,DB01197,Captopril
,9215971,flow rate,"Of this acetonitrile solution (100 microliters) was injected on an ODS reverse phase HPLC column (chromatography conditions; mobile phase; acetonitrile-water-acetic acid (225:270:5, v/v/v), flow rate; 1 ml min-1, detection; UV at 263 nm).",Determination of captopril in human serum by high performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215971/),[ml] / [min],1,72647,DB01197,Captopril
exceeds,9215971,Recovery,Recovery exceeds 94% and analytical responses are linear over captopril concentration range from 50 up to 1000 ng ml-1.,Determination of captopril in human serum by high performance liquid chromatography using solid-phase extraction. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9215971/),%,94,72648,DB01197,Captopril
,32655663,apparent total body clearance (Cl/F,"Conversely, H. sabdariffa L. extract increased the apparent total body clearance (Cl/F, 0.0257 ± 0.0115 vs. 0.1418 ± 0.0338 mL/h·kg) and the apparent volume of distribution (Vd/F, 0.0541 ± 0.0226 vs. 0.3205 ± 0.0790 mL/kg).",Pharmacokinetic Herb-Drug Interaction between Hibiscus sabdariffa Calyces Aqueous Extract and Captopril in Rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32655663/),[ml] / [h·kg],0.0257,72995,DB01197,Captopril
,32655663,apparent total body clearance (Cl/F,"Conversely, H. sabdariffa L. extract increased the apparent total body clearance (Cl/F, 0.0257 ± 0.0115 vs. 0.1418 ± 0.0338 mL/h·kg) and the apparent volume of distribution (Vd/F, 0.0541 ± 0.0226 vs. 0.3205 ± 0.0790 mL/kg).",Pharmacokinetic Herb-Drug Interaction between Hibiscus sabdariffa Calyces Aqueous Extract and Captopril in Rats. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32655663/),[ml] / [h·kg],0.1418,72996,DB01197,Captopril
,32655663,apparent volume of distribution (Vd/F,"Conversely, H. sabdariffa L. extract increased the apparent total body clearance (Cl/F, 0.0257 ± 0.0115 vs. 0.1418 ± 0.0338 mL/h·kg) and the apparent volume of distribution (Vd/F, 0.0541 ± 0.0226 vs. 0.3205 ± 0.0790 mL/kg).",Pharmacokinetic Herb-Drug Interaction between Hibiscus sabdariffa Calyces Aqueous Extract and Captopril in Rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32655663/),[ml] / [kg],0.0541,72997,DB01197,Captopril
,32655663,apparent volume of distribution (Vd/F,"Conversely, H. sabdariffa L. extract increased the apparent total body clearance (Cl/F, 0.0257 ± 0.0115 vs. 0.1418 ± 0.0338 mL/h·kg) and the apparent volume of distribution (Vd/F, 0.0541 ± 0.0226 vs. 0.3205 ± 0.0790 mL/kg).",Pharmacokinetic Herb-Drug Interaction between Hibiscus sabdariffa Calyces Aqueous Extract and Captopril in Rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32655663/),[ml] / [kg],0.3205,72998,DB01197,Captopril
,3899460,time of maximal plasma concentration (tmax),"In the fasting state, the time of maximal plasma concentration (tmax) was 1 hour for free captopril, 1.7 hours for protein-conjugated captopril, and 1.6 hours for total captopril.",Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),h,1,77561,DB01197,Captopril
,3899460,time of maximal plasma concentration (tmax),"In the fasting state, the time of maximal plasma concentration (tmax) was 1 hour for free captopril, 1.7 hours for protein-conjugated captopril, and 1.6 hours for total captopril.",Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),h,1.7,77562,DB01197,Captopril
,3899460,time of maximal plasma concentration (tmax),"In the fasting state, the time of maximal plasma concentration (tmax) was 1 hour for free captopril, 1.7 hours for protein-conjugated captopril, and 1.6 hours for total captopril.",Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),h,1.6,77563,DB01197,Captopril
,3899460,biologic t1/2,"The biologic t1/2 of free, protein-conjugated, and total captopril was 1.9, 4.2, and 5 hours, respectively.",Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),h,1.9,77564,DB01197,Captopril
,3899460,biologic t1/2,"The biologic t1/2 of free, protein-conjugated, and total captopril was 1.9, 4.2, and 5 hours, respectively.",Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),h,4.2,77565,DB01197,Captopril
,3899460,biologic t1/2,"The biologic t1/2 of free, protein-conjugated, and total captopril was 1.9, 4.2, and 5 hours, respectively.",Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),h,5,77566,DB01197,Captopril
,3899460,tmax,"In the fed state, neither tmax nor t1/2 changed, except that the tmax of free captopril was prolonged to 1.9 hours (P less than 0.01).",Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),h,1.9,77567,DB01197,Captopril
,3899460,Cumulative,Cumulative urinary excretion of free captopril at 8 hours was 35% of the drug administered in the fasting state and that of total captopril at 24 hours was 59%.,Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),%,35,77568,DB01197,Captopril
,3899460,Cumulative,Cumulative urinary excretion of free captopril at 8 hours was 35% of the drug administered in the fasting state and that of total captopril at 24 hours was 59%.,Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),%,59,77569,DB01197,Captopril
,3899460,urinary excretion,Cumulative urinary excretion of free captopril at 8 hours was 35% of the drug administered in the fasting state and that of total captopril at 24 hours was 59%.,Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),%,35,77570,DB01197,Captopril
,3899460,urinary excretion,Cumulative urinary excretion of free captopril at 8 hours was 35% of the drug administered in the fasting state and that of total captopril at 24 hours was 59%.,Pharmacokinetics of a new angiotensin I converting enzyme inhibitor (alacepril) after oral dosing in fasting or fed states. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3899460/),%,59,77571,DB01197,Captopril
,7032776,clearance,"At 30 minutes after the start of hemodialysis, the clearance of Captopril was 80 +/- 14.2 ml/min, whereas that of creatinine was 123.4 +/- 8.8 ml/min and that of BUN was 144.1 +/- 7.2 ml/min.",Captopril (SQ 14225) clearance during hemodialysis treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032776/),[ml] / [min],80,84669,DB01197,Captopril
,7032776,clearance,"At 30 minutes after the start of hemodialysis, the clearance of Captopril was 80 +/- 14.2 ml/min, whereas that of creatinine was 123.4 +/- 8.8 ml/min and that of BUN was 144.1 +/- 7.2 ml/min.",Captopril (SQ 14225) clearance during hemodialysis treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032776/),[ml] / [min],123.4,84670,DB01197,Captopril
,7032776,clearance,"At 30 minutes after the start of hemodialysis, the clearance of Captopril was 80 +/- 14.2 ml/min, whereas that of creatinine was 123.4 +/- 8.8 ml/min and that of BUN was 144.1 +/- 7.2 ml/min.",Captopril (SQ 14225) clearance during hemodialysis treatment. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7032776/),[ml] / [min],144.1,84671,DB01197,Captopril
,9498669,recovery,"The assay was linear from 10 to 5000 ng/ml with a mean recovery following solvent extraction at 50, 200 and 1000 ng/ml of 77%.",Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498669/),%,77,90429,DB01197,Captopril
,9498669,Cmax,"Analysis of captopril concentrations in plasma samples from 20 volunteers following oral administration of 100 mg of captopril provided the following pharmacokinetic data (mean+/-S.D.): Cmax, 1470+/-467 ng/ml; AUC(0-infinity), 1736+/-481 ng/ml.h; Tmax, 0.73 h; k(e), 0.468+/-0.122 h(-1); elimination half life, 1.58/-0.41 h.",Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498669/),[ng] / [ml],1470,90430,DB01197,Captopril
,9498669,AUC(0-infinity),"Analysis of captopril concentrations in plasma samples from 20 volunteers following oral administration of 100 mg of captopril provided the following pharmacokinetic data (mean+/-S.D.): Cmax, 1470+/-467 ng/ml; AUC(0-infinity), 1736+/-481 ng/ml.h; Tmax, 0.73 h; k(e), 0.468+/-0.122 h(-1); elimination half life, 1.58/-0.41 h.",Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498669/),[ng] / [h·ml],1736,90431,DB01197,Captopril
,9498669,Tmax,"Analysis of captopril concentrations in plasma samples from 20 volunteers following oral administration of 100 mg of captopril provided the following pharmacokinetic data (mean+/-S.D.): Cmax, 1470+/-467 ng/ml; AUC(0-infinity), 1736+/-481 ng/ml.h; Tmax, 0.73 h; k(e), 0.468+/-0.122 h(-1); elimination half life, 1.58/-0.41 h.",Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498669/),h,0.73,90432,DB01197,Captopril
,9498669,k(e),"Analysis of captopril concentrations in plasma samples from 20 volunteers following oral administration of 100 mg of captopril provided the following pharmacokinetic data (mean+/-S.D.): Cmax, 1470+/-467 ng/ml; AUC(0-infinity), 1736+/-481 ng/ml.h; Tmax, 0.73 h; k(e), 0.468+/-0.122 h(-1); elimination half life, 1.58/-0.41 h.",Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498669/),1/[h],0.468,90433,DB01197,Captopril
,9498669,elimination half life,"Analysis of captopril concentrations in plasma samples from 20 volunteers following oral administration of 100 mg of captopril provided the following pharmacokinetic data (mean+/-S.D.): Cmax, 1470+/-467 ng/ml; AUC(0-infinity), 1736+/-481 ng/ml.h; Tmax, 0.73 h; k(e), 0.468+/-0.122 h(-1); elimination half life, 1.58/-0.41 h.",Improved analytical procedure for the measurement of captopril in human plasma by gas chromatography--mass spectrometry and its application to pharmacokinetic studies. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9498669/),h,1.58,90434,DB01197,Captopril
,3014110,area under the serum concentration-time curve (AUC0-120h,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[h·ng] / [ml],1231,97037,DB01197,Captopril
,3014110,area under the serum concentration-time curve (AUC0-120h,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[h·ng] / [ml],1029,97038,DB01197,Captopril
,3014110,peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[ng] / [ml],86,97039,DB01197,Captopril
,3014110,peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),[ng] / [ml],69,97040,DB01197,Captopril
,3014110,time to peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),h,6.2,97041,DB01197,Captopril
,3014110,time to peak lisinopril serum concentration,"No significant differences existed between fasting and fed regimens in the mean +/- SD area under the serum concentration-time curve (AUC0-120h; 1231 +/- 620 versus 1029 +/- 254 ng X h X ml-1), peak lisinopril serum concentration (86 +/- 48 versus 69 +/- 19 ng/mL), or time to peak lisinopril serum concentration (6.2 +/- 1.1 versus 6.8 +/- 1.0 h).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),h,6.8,97042,DB01197,Captopril
,3014110,urinary excretion,Five-day urinary excretion of lisinopril was not altered by food (5.3 +/- 3.0 versus 5.1 +/- 2.0 mg).,"Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),mg,5.3,97043,DB01197,Captopril
,3014110,urinary excretion,Five-day urinary excretion of lisinopril was not altered by food (5.3 +/- 3.0 versus 5.1 +/- 2.0 mg).,"Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),mg,5.1,97044,DB01197,Captopril
,3014110,bioavailability,"Based on the urinary data, the mean +/- SD bioavailability of lisinopril was not different following fasting or fed regimens (27 +/- 15 versus 26 +/- 10%).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),%,27,97045,DB01197,Captopril
,3014110,bioavailability,"Based on the urinary data, the mean +/- SD bioavailability of lisinopril was not different following fasting or fed regimens (27 +/- 15 versus 26 +/- 10%).","Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3014110/),%,26,97046,DB01197,Captopril
,2311339,partial metabolic clearance,"Food significantly decreased the relative availability of perindoprilat by 35% +/- 42%, the fractional urinary excretion of perindoprilat from 19% +/- 7% to 13% +/- 4% (p less than 0.05), and the partial metabolic clearance of perindopril to perindoprilat from 102 +/- 57 ml.min-1 to 72 +/- 32 ml.min-1 (p less than 0.05).",Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311339/),[ml] / [min],102,97970,DB01197,Captopril
,2311339,partial metabolic clearance,"Food significantly decreased the relative availability of perindoprilat by 35% +/- 42%, the fractional urinary excretion of perindoprilat from 19% +/- 7% to 13% +/- 4% (p less than 0.05), and the partial metabolic clearance of perindopril to perindoprilat from 102 +/- 57 ml.min-1 to 72 +/- 32 ml.min-1 (p less than 0.05).",Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2311339/),[ml] / [min],72,97971,DB01197,Captopril
,9480462,Coefficient A,Coefficient A in basic renoscintigraphy did not differ in patients with EH and RVH and was 45.81 +/- 3.02% and 44.66 +/- 6.17% respectively.,[Usefulness of angiotensin converting enzyme inhibitors in the diagnosis of renovascular hypertension. Comparison of the effect of angiotensin converting enzyme inhibition on reno-scintigraphic curves with DTPA in patients with essential and renovascular hypertension]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9480462/),%,45.81,100940,DB01197,Captopril
,9480462,Coefficient A,Coefficient A in basic renoscintigraphy did not differ in patients with EH and RVH and was 45.81 +/- 3.02% and 44.66 +/- 6.17% respectively.,[Usefulness of angiotensin converting enzyme inhibitors in the diagnosis of renovascular hypertension. Comparison of the effect of angiotensin converting enzyme inhibition on reno-scintigraphic curves with DTPA in patients with essential and renovascular hypertension]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9480462/),%,44.66,100941,DB01197,Captopril
,1711623,Peak serum concentration,"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),[ng] / [ml],2.1,111504,DB01197,Captopril
,1711623,Peak serum concentration,"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),[ng] / [ml],2.0,111505,DB01197,Captopril
,1711623,time to peak,"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),h,1.1,111506,DB01197,Captopril
,1711623,time to peak,"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),h,1.8,111507,DB01197,Captopril
,1711623,terminal half-life (t1/2 alpha),"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),h,10.9,111508,DB01197,Captopril
,1711623,terminal half-life (t1/2 alpha),"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),h,8.7,111509,DB01197,Captopril
,1711623,area under the concentration-time curve to 24 h,"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),[h·ng] / [ml],26.9,111510,DB01197,Captopril
,1711623,area under the concentration-time curve to 24 h,"Peak serum concentration of digoxin (SCD) before and after captopril was 2.1 +/- 0.2, mean +/- SEM, and 2.0 +/- 0.1 ng/ml; the time to peak was 1.1 +/- 0.2 and 1.8 +/- 0.3 h; the terminal half-life (t1/2 alpha) was 10.9 +/- 1.0 and 8.7 +/- 0.9 h, and the area under the concentration-time curve to 24 h was 26.9 +/- 2.4 and 27.6 +/- 2.0 ng.h/ml.",The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1711623/),[h·ng] / [ml],27.6,111511,DB01197,Captopril
,1782836,Peak captopril concentrations,"Peak captopril concentrations were achieved between half an hour and 2 h, and ranged between 100 and 547 ng/ml.","Captopril pharmacokinetics, blood pressure response and plasma renin activity in normotensive children with renal scarring. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782836/),[ng] / [ml],100 and 547,115536,DB01197,Captopril
,1782836,elimination half-time (T1/2),"Mean elimination half-time (T1/2) was 1.5 h, ranging between 0.98 and 2.3 h.","Captopril pharmacokinetics, blood pressure response and plasma renin activity in normotensive children with renal scarring. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1782836/),h,1.5,115537,DB01197,Captopril
,6324834,"t1/2, alpha","Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.","Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6324834/),h,0.45,122518,DB01197,Captopril
,6324834,tmax,"Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.","Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6324834/),h,0.98,122519,DB01197,Captopril
,6324834,Cmax,"Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.","Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6324834/),[mg] / [l],1.31,122520,DB01197,Captopril
,6324834,"t1/2,z","Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.","Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6324834/),h,0.66,122521,DB01197,Captopril
,6324834,V,"Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.","Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6324834/),[1] / [kg],0.614,122522,DB01197,Captopril
,6324834,CLtot,"Free unchanged captopril pharmacokinetic parameters were: t1/2, alpha: 0.45 +/- 0.06 h; tmax: 0.98 +/- 0.13 h; Cmax: 1.31 +/- 0.20 mg l-1; t1/2,z: 0.66 +/- 0.13 h; V: 0.614 +/- 0.104 1 kg-1 and CLtot: 0.690 +/- 0.082 l h-1 kg-1.","Captopril: pharmacokinetics, antihypertensive and biological effects in hypertensive patients. ",CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6324834/),[l] / [h·kg],0.690,122523,DB01197,Captopril
,6344870,maximum concentration,"A maximum concentration of captopril was achieved at 30 min in tissues studied, being substantially higher in kidney (14.2 micrograms/g), with lesser amounts occurring in liver, lung, heart, blood cells, spleen and plasma in that order.","Tissue distribution of captopril, reducible captopril conjugates and S-methylcaptopril in the rat. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6344870/),[μg] / [g],14.2,123584,DB01197,Captopril
,2052527,E,"As individual eliminating organs, the gut and liver each had a high intrinsic capability to hydrolyze zofenopril; E values ranged from 45 to 89%.",Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052527/),%,45 to 89,123685,DB01197,Captopril
,2052527,E,"The lungs were found to have low, but measurable, hydrolytic activity with estimated E values that ranged from 5 to 26%.",Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052527/),%,5 to 26,123686,DB01197,Captopril
,2052527,mean residence time,Zofenopril was rapidly eliminated after parenteral administration; mean residence time values were 2 min and the elimination half-life values (intraarterial route only) were 9 min.,Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052527/),min,2,123687,DB01197,Captopril
,2052527,elimination half-life,Zofenopril was rapidly eliminated after parenteral administration; mean residence time values were 2 min and the elimination half-life values (intraarterial route only) were 9 min.,Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2052527/),min,9,123688,DB01197,Captopril
,2050174,Cmax,"Mean pharmacokinetic parameters for unchanged captopril after sublingual administration were: Cmax, 234 ng.ml-1; tmax, 45 min; AUC (0-3 h), 15.1 micrograms.",Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),[ng] / [ml],234,130101,DB01197,Captopril
,2050174,tmax,"Mean pharmacokinetic parameters for unchanged captopril after sublingual administration were: Cmax, 234 ng.ml-1; tmax, 45 min; AUC (0-3 h), 15.1 micrograms.",Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),min,45,130102,DB01197,Captopril
,2050174,AUC (0-3 h),"Mean pharmacokinetic parameters for unchanged captopril after sublingual administration were: Cmax, 234 ng.ml-1; tmax, 45 min; AUC (0-3 h), 15.1 micrograms.",Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),μg,15.1,130103,DB01197,Captopril
,2050174,Cmax,"Mean pharmacokinetic parameters for unchanged captopril after peroral administration were; Cmax, 228 ng.ml-1; tmax, 75 min; AUC (0-3 h), 17.0 micrograms.",Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),[ng] / [ml],228,130104,DB01197,Captopril
,2050174,tmax,"Mean pharmacokinetic parameters for unchanged captopril after peroral administration were; Cmax, 228 ng.ml-1; tmax, 75 min; AUC (0-3 h), 17.0 micrograms.",Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),min,75,130105,DB01197,Captopril
,2050174,AUC (0-3 h),"Mean pharmacokinetic parameters for unchanged captopril after peroral administration were; Cmax, 228 ng.ml-1; tmax, 75 min; AUC (0-3 h), 17.0 micrograms.",Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),μg,17.0,130106,DB01197,Captopril
,2050174,tmax,tmax for PRA was 86 min for sublingual captopril and 113 min for perorally administered drug.,Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),min,86,130107,DB01197,Captopril
,2050174,tmax,tmax for PRA was 86 min for sublingual captopril and 113 min for perorally administered drug.,Sublingual captopril--a pharmacokinetic and pharmacodynamic evaluation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2050174/),min,113,130108,DB01197,Captopril
,2144379,Recovery efficiencies,Recovery efficiencies ranged from 97.2 to 109.4%.,"A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,97.2 to,145680,DB01197,Captopril
,2144379,Recovery efficiencies,Recovery efficiencies ranged from 97.2 to 109.4%.,"A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,109,145681,DB01197,Captopril
,2144379,Cross-reactivities,"Cross-reactivities for prodrug (SQ 28,555) and phenolic SQ 27,519 were 5 and 9%, respectively.","A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,5,145682,DB01197,Captopril
,2144379,Cross-reactivities,"Cross-reactivities for prodrug (SQ 28,555) and phenolic SQ 27,519 were 5 and 9%, respectively.","A radioimmunoassay for SQ 27,519, the active phosphinic acid-carboxylic diacid of the prodrug fosinopril in human serum. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2144379/),%,9,145683,DB01197,Captopril
,3297733,peak plasma concentration,The mean peak plasma concentration of captopril was 2.5 times higher (0.447 micrograms X ml-1 vs 0.181 micrograms X ml-1) and the concentrations of the disulfides 4 times higher (3.62 micrograms X ml-1 vs 0.924 micrograms X ml-1) in the uraemic patients.,The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3297733/),[μg] / [ml],0.447,146437,DB01197,Captopril
,3297733,peak plasma concentration,The mean peak plasma concentration of captopril was 2.5 times higher (0.447 micrograms X ml-1 vs 0.181 micrograms X ml-1) and the concentrations of the disulfides 4 times higher (3.62 micrograms X ml-1 vs 0.924 micrograms X ml-1) in the uraemic patients.,The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3297733/),[μg] / [ml],0.181,146438,DB01197,Captopril
,3297733,peak plasma concentration,The mean peak plasma concentration of captopril was 2.5 times higher (0.447 micrograms X ml-1 vs 0.181 micrograms X ml-1) and the concentrations of the disulfides 4 times higher (3.62 micrograms X ml-1 vs 0.924 micrograms X ml-1) in the uraemic patients.,The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3297733/),[μg] / [ml],3.62,146439,DB01197,Captopril
,3297733,peak plasma concentration,The mean peak plasma concentration of captopril was 2.5 times higher (0.447 micrograms X ml-1 vs 0.181 micrograms X ml-1) and the concentrations of the disulfides 4 times higher (3.62 micrograms X ml-1 vs 0.924 micrograms X ml-1) in the uraemic patients.,The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3297733/),[μg] / [ml],0.924,146440,DB01197,Captopril
,3297733,apparent plasma half-time,The apparent plasma half-time was 46 +/- 19 h.,The pharmacokinetics of captopril and captopril disulfide conjugates in uraemic patients on maintenance dialysis: comparison with patients with normal renal function. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3297733/),h,46,146441,DB01197,Captopril
,6989546,Tmax,Average absorption parameters for unchanged captopril in blood were Tmax 0.93 +/- 0.08 hr and Cmax 800 +/- 76 ng/ml.,Disposition of captopril in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6989546/),h,0.93,148126,DB01197,Captopril
,6989546,Cmax,Average absorption parameters for unchanged captopril in blood were Tmax 0.93 +/- 0.08 hr and Cmax 800 +/- 76 ng/ml.,Disposition of captopril in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6989546/),[ng] / [ml],800,148127,DB01197,Captopril
,6989546,Tmax,"For total radioactivity in blood the values were Tmax 1.05 +/- 0.08 hr and Cmax 1,580 +/- 90 ng/ml (as captopril equivalents).",Disposition of captopril in normal subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6989546/),h,1.05,148128,DB01197,Captopril
,6989546,Cmax,"For total radioactivity in blood the values were Tmax 1.05 +/- 0.08 hr and Cmax 1,580 +/- 90 ng/ml (as captopril equivalents).",Disposition of captopril in normal subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6989546/),[ng] / [ml],"1,580",148129,DB01197,Captopril
,2795963,area under the curve (AUC),"The area under the curve (AUC) of captopril in the elderly group (335.4 +/- 98.6 hr.2ng/ml) was significantly greater than in the young group (186.7 +/- 79.9) (p less than 0.005), while no significant differences in Cmax, Tmax and T1/2 were observed.",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),2·h,335.4,149720,DB01197,Captopril
,2795963,area under the curve (AUC),"The area under the curve (AUC) of captopril in the elderly group (335.4 +/- 98.6 hr.2ng/ml) was significantly greater than in the young group (186.7 +/- 79.9) (p less than 0.005), while no significant differences in Cmax, Tmax and T1/2 were observed.",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),[ng] / [ml],186.7,149721,DB01197,Captopril
,2795963,Cmax,"Cmax and AUC of nifedipine in the elderly tended to be higher than in the young group (303.5 v.s. 210.0 ng/ml and 1258.9 v.s. 725.1 hr.ng/ml, p less than 0.1, respectively).",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),[ng] / [ml],303.5,149722,DB01197,Captopril
,2795963,AUC,"Cmax and AUC of nifedipine in the elderly tended to be higher than in the young group (303.5 v.s. 210.0 ng/ml and 1258.9 v.s. 725.1 hr.ng/ml, p less than 0.1, respectively).",[Pharmacokinetics and pharmacodynamics of antihypertensive drugs in the elderly]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2795963/),[h·ng] / [ml],1258.9,149723,DB01197,Captopril
,3034035,trough levels,"Mean serum digoxin concentration was not significantly influenced by ramipril coadministration with trough levels of 0.90 +/- 0.24 before, 0.93 +/- 0.38 during and 0.82 +/- 0.33 ng/ml after ramipril medication.",Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034035/),[ng] / [ml],0.90,154703,DB01197,Captopril
,3034035,trough levels,"Mean serum digoxin concentration was not significantly influenced by ramipril coadministration with trough levels of 0.90 +/- 0.24 before, 0.93 +/- 0.38 during and 0.82 +/- 0.33 ng/ml after ramipril medication.",Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034035/),[ng] / [ml],0.93,154704,DB01197,Captopril
,3034035,trough levels,"Mean serum digoxin concentration was not significantly influenced by ramipril coadministration with trough levels of 0.90 +/- 0.24 before, 0.93 +/- 0.38 during and 0.82 +/- 0.33 ng/ml after ramipril medication.",Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3034035/),[ng] / [ml],0.82,154705,DB01197,Captopril
,3025754,time to maximal concentration,"The pharmacokinetic parameters for plasma free unchanged captopril were time to maximal concentration 1.1 +/- 0.3 h, maximal plasma concentration 387 +/- 75 ng X ml-1, elimination half-life 1.0 +/- 0.3 h, and the area under the concentration-time curve 711 +/- 144 ng X h X ml-1.",Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025754/),h,1.1,156172,DB01197,Captopril
,3025754,maximal plasma concentration,"The pharmacokinetic parameters for plasma free unchanged captopril were time to maximal concentration 1.1 +/- 0.3 h, maximal plasma concentration 387 +/- 75 ng X ml-1, elimination half-life 1.0 +/- 0.3 h, and the area under the concentration-time curve 711 +/- 144 ng X h X ml-1.",Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025754/),[ng] / [ml],387,156173,DB01197,Captopril
,3025754,elimination half-life,"The pharmacokinetic parameters for plasma free unchanged captopril were time to maximal concentration 1.1 +/- 0.3 h, maximal plasma concentration 387 +/- 75 ng X ml-1, elimination half-life 1.0 +/- 0.3 h, and the area under the concentration-time curve 711 +/- 144 ng X h X ml-1.",Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025754/),h,1.0,156174,DB01197,Captopril
,3025754,area under the concentration-time curve,"The pharmacokinetic parameters for plasma free unchanged captopril were time to maximal concentration 1.1 +/- 0.3 h, maximal plasma concentration 387 +/- 75 ng X ml-1, elimination half-life 1.0 +/- 0.3 h, and the area under the concentration-time curve 711 +/- 144 ng X h X ml-1.",Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025754/),[h·ng] / [ml],711,156175,DB01197,Captopril
,3025754,time to maximal concentration,"For plasma total captopril (the sum of free unchanged captopril and its disulfide compounds) the values were time to maximal concentration 3.5 +/- 0.6 h and maximal plasma concentration 2,777 +/- 429 ng X ml-1.",Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025754/),h,3.5,156176,DB01197,Captopril
,3025754,maximal plasma concentration,"For plasma total captopril (the sum of free unchanged captopril and its disulfide compounds) the values were time to maximal concentration 3.5 +/- 0.6 h and maximal plasma concentration 2,777 +/- 429 ng X ml-1.",Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3025754/),[ng] / [ml],"2,777",156177,DB01197,Captopril
,9643616,steady state (t,"At presumed ICG steady state (t=45 min), subjects were dosed with oral nifedipine (20 mg), captopril (50 mg) or placebo.",The influence of nifedipine and captopril on liver blood flow in healthy subjects. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643616/),min,45,176948,DB01197,Captopril
,9643616,Portal venous flow,"Portal venous flow was 15% (+ 5, + 86 ml min(-1)) higher compared to placebo after nifedipine but not after captopril (-3%; -49, +33 ml min(-1)).",The influence of nifedipine and captopril on liver blood flow in healthy subjects. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643616/),[ml] / [min],5,176949,DB01197,Captopril
,9643616,Portal venous flow,"Portal venous flow was 15% (+ 5, + 86 ml min(-1)) higher compared to placebo after nifedipine but not after captopril (-3%; -49, +33 ml min(-1)).",The influence of nifedipine and captopril on liver blood flow in healthy subjects. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9643616/),[ml] / [min],86,176950,DB01197,Captopril
,2292772,recovery,"After the iv dose of 14C-3, the 0-96-h recovery of radioactivity averaged 76 and 16% of the dose in urine and feces, respectively, indicating substantial biliary secretion.",Disposition of zofenopril calcium in healthy subjects. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),%,76,179726,DB01197,Captopril
,2292772,recovery,"After the iv dose of 14C-3, the 0-96-h recovery of radioactivity averaged 76 and 16% of the dose in urine and feces, respectively, indicating substantial biliary secretion.",Disposition of zofenopril calcium in healthy subjects. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),%,16,179727,DB01197,Captopril
,2292772,excretion of,"After the oral dose of 14C-1, excretion of radioactivity averaged 70% (urine) and 26% (feces).",Disposition of zofenopril calcium in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),%,70,179728,DB01197,Captopril
,2292772,excretion of,"After the oral dose of 14C-1, excretion of radioactivity averaged 70% (urine) and 26% (feces).",Disposition of zofenopril calcium in healthy subjects. ,fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),%,26,179729,DB01197,Captopril
,2292772,oral bioavailability,The oral absorption of 1 was almost complete and the oral bioavailability of 2 averaged approximately 70%.,Disposition of zofenopril calcium in healthy subjects. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),%,70,179730,DB01197,Captopril
,2292772,terminal elimination half-life,The terminal elimination half-life for 2 after the iv dose averaged 5.5 h.,Disposition of zofenopril calcium in healthy subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),h,5.5,179731,DB01197,Captopril
,2292772,Whole body clearance,"Whole body clearance, renal clearance, nonrenal clearance, and Vdss averaged 11.4, 3.1, and 8.3 mL/min/kg and 1.3 L/kg, respectively.",Disposition of zofenopril calcium in healthy subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),[ml] / [kg·min],11.4,179732,DB01197,Captopril
,2292772,renal clearance,"Whole body clearance, renal clearance, nonrenal clearance, and Vdss averaged 11.4, 3.1, and 8.3 mL/min/kg and 1.3 L/kg, respectively.",Disposition of zofenopril calcium in healthy subjects. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),[ml] / [kg·min],3.1,179733,DB01197,Captopril
,2292772,nonrenal clearance,"Whole body clearance, renal clearance, nonrenal clearance, and Vdss averaged 11.4, 3.1, and 8.3 mL/min/kg and 1.3 L/kg, respectively.",Disposition of zofenopril calcium in healthy subjects. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),[ml] / [kg·min],3.1,179734,DB01197,Captopril
,2292772,Vdss,"Whole body clearance, renal clearance, nonrenal clearance, and Vdss averaged 11.4, 3.1, and 8.3 mL/min/kg and 1.3 L/kg, respectively.",Disposition of zofenopril calcium in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),[ml] / [kg·min],8.3,179735,DB01197,Captopril
,2292772,Vdss,"Whole body clearance, renal clearance, nonrenal clearance, and Vdss averaged 11.4, 3.1, and 8.3 mL/min/kg and 1.3 L/kg, respectively.",Disposition of zofenopril calcium in healthy subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2292772/),[l] / [kg],1.3,179736,DB01197,Captopril
,8201530,t1/2 alpha,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),min,4.9,184827,DB01197,Captopril
,8201530,t1/2 beta,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),h,2.76,184828,DB01197,Captopril
,8201530,Vdss,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[l] / [kg],3.86,184829,DB01197,Captopril
,8201530,plasma clearance,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[l] / [kg],2.22,184830,DB01197,Captopril
,8201530,AUC,"Kinetics were as follows: t1/2 alpha = 4.9 +/- 0.2 min, t1/2 beta = 2.76 +/- 0.79 h, Vdss = 3.86 +/- 1.04 L kg-1, plasma clearance = 2.22 +/- 0.39 L kg-1, and AUC = 1445 +/- 266 ng h mL-1.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[h·ng] / [ml],1445,184831,DB01197,Captopril
,8201530,maximum plasma concentration,"After 30 mg kg-1 oral dose, maximum plasma concentration, tmax and AUC of YM-21095 were 28.8 +/- 9.6 ng mL-1, 0.25 h and 23.6 +/- 7.7 ng h mL-1, respectively.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[ng] / [ml],28.8,184832,DB01197,Captopril
,8201530,tmax,"After 30 mg kg-1 oral dose, maximum plasma concentration, tmax and AUC of YM-21095 were 28.8 +/- 9.6 ng mL-1, 0.25 h and 23.6 +/- 7.7 ng h mL-1, respectively.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),h,0.25,184833,DB01197,Captopril
,8201530,AUC,"After 30 mg kg-1 oral dose, maximum plasma concentration, tmax and AUC of YM-21095 were 28.8 +/- 9.6 ng mL-1, 0.25 h and 23.6 +/- 7.7 ng h mL-1, respectively.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[h·ng] / [ml],23.6,184834,DB01197,Captopril
,8201530,Systemic bioavailability,Systemic bioavailability as determined on the basis of the ratio of AUC after intravenous and oral dose was 0.16 +/- 0.04%.,"Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),%,0.16,184835,DB01197,Captopril
,8201530,Maximum plasma concentration,"Maximum plasma concentration of YM-21095 after 30 mg kg-1 oral dose to monkeys was 71.8 +/- 41.5 ng mL-1, which was reached 0.5 h after the dose.","Pharmacokinetics and cardiovascular effects of YM-21095, a novel renin inhibitor, in dogs and monkeys. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8201530/),[ng] / [ml],71.8,184836,DB01197,Captopril
>,30695689,gastric retention,"Moreover, radiographic study exhibited gastric retention of prepared tablets >12 h.",Formulation of zein based compression coated floating tablets for enhanced gastric retention and tunable drug release. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30695689/),h,12,188358,DB01197,Captopril
,1712266,half-life,"Using this method, we showed that single oral doses of cilazapril 4 mg, captopril 25 mg and enalapril 10mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacological half-life of about 4 hours for cilazapril.",Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712266/),h,4,192097,DB01197,Captopril
,1712266,apparent Ki-dose,"The dose representing 50% inhibition of ACE activity (apparent Ki-dose) was about 0.6mg, 3 hours after cilazapril administration.",Clinical pharmacodynamic studies with cilazapril and a combination of cilazapril and propranolol. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1712266/),mg,0.6,192098,DB01197,Captopril
,17145205,retention time,"The retention time was 1.45 and 1.37 min for captopril and enalapril, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),min,1.45,194617,DB01197,Captopril
,17145205,retention time,"The retention time was 1.45 and 1.37 min for captopril and enalapril, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),min,1.37,194618,DB01197,Captopril
,17145205,overall mean recovery,"The overall mean recovery, using SPE extraction with OASIS HLB cartridges, was found to be 107.2+/-9.5 and 100.04+/-2%, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),%,107.2,194619,DB01197,Captopril
,17145205,overall mean recovery,"The overall mean recovery, using SPE extraction with OASIS HLB cartridges, was found to be 107.2+/-9.5 and 100.04+/-2%, respectively.","Determination of captopril in human plasma, using solid phase extraction and high-performance liquid chromatography, coupled to mass spectrometry: application to bioequivalence study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17145205/),%,100.04,194620,DB01197,Captopril
,6381858,body clearance (ClB),The body clearance (ClB) of captopril decreased steadily with decreasing creatinine clearance (ClCr) from 5.2 ml/min/kg for mild renal failure patients to 1.6 ml/min/kg for hemodialysis patients during an interdialytic period.,Elimination kinetics of captopril in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),[ml] / [kg·min],1.6,199034,DB01197,Captopril
,6381858,renal,"In patients with mild renal impairment, renal and nonrenal clearances of captopril averaged 2.2 and 3.0 ml/min/kg, respectively, and fell (P less than 0.001) to 0.2 and 1.5 ml/min/kg in patients with severe renal impairment.",Elimination kinetics of captopril in patients with renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),[ml] / [kg·min],2.2,199035,DB01197,Captopril
,6381858,renal,"In patients with mild renal impairment, renal and nonrenal clearances of captopril averaged 2.2 and 3.0 ml/min/kg, respectively, and fell (P less than 0.001) to 0.2 and 1.5 ml/min/kg in patients with severe renal impairment.",Elimination kinetics of captopril in patients with renal failure. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),[ml] / [kg·min],0.2,199036,DB01197,Captopril
,6381858,nonrenal clearances,"In patients with mild renal impairment, renal and nonrenal clearances of captopril averaged 2.2 and 3.0 ml/min/kg, respectively, and fell (P less than 0.001) to 0.2 and 1.5 ml/min/kg in patients with severe renal impairment.",Elimination kinetics of captopril in patients with renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),[ml] / [kg·min],3.0,199037,DB01197,Captopril
,6381858,nonrenal clearances,"In patients with mild renal impairment, renal and nonrenal clearances of captopril averaged 2.2 and 3.0 ml/min/kg, respectively, and fell (P less than 0.001) to 0.2 and 1.5 ml/min/kg in patients with severe renal impairment.",Elimination kinetics of captopril in patients with renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),[ml] / [kg·min],0.2,199038,DB01197,Captopril
,6381858,nonrenal clearances,"In patients with mild renal impairment, renal and nonrenal clearances of captopril averaged 2.2 and 3.0 ml/min/kg, respectively, and fell (P less than 0.001) to 0.2 and 1.5 ml/min/kg in patients with severe renal impairment.",Elimination kinetics of captopril in patients with renal failure. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),[ml] / [kg·min],1.5,199039,DB01197,Captopril
,6381858,renal excretion,"The 48-hr renal excretion of captopril averaged 29, 21, and 8% of the dose in the mild, moderate, and severe renally impaired groups.",Elimination kinetics of captopril in patients with renal failure. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),%,29,199040,DB01197,Captopril
,6381858,renal excretion,"The 48-hr renal excretion of captopril averaged 29, 21, and 8% of the dose in the mild, moderate, and severe renally impaired groups.",Elimination kinetics of captopril in patients with renal failure. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),%,21,199041,DB01197,Captopril
,6381858,renal excretion,"The 48-hr renal excretion of captopril averaged 29, 21, and 8% of the dose in the mild, moderate, and severe renally impaired groups.",Elimination kinetics of captopril in patients with renal failure. ,FR-Q43,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),%,8,199042,DB01197,Captopril
,6381858,clearance,"In five additional hemodialysis patients, the mean dialyzer clearance of captopril averaged 120 ml/min.",Elimination kinetics of captopril in patients with renal failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6381858/),[ml] / [min],120,199043,DB01197,Captopril
,2068835,elimination half-life,"The elimination half-life of quinaprilat is three hours, but is prolonged up to 11 hours in patients with renal dysfunction.",Quinapril: a new second-generation ACE inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2068835/),h,three,203266,DB01197,Captopril
,2068835,elimination half-life,"The elimination half-life of quinaprilat is three hours, but is prolonged up to 11 hours in patients with renal dysfunction.",Quinapril: a new second-generation ACE inhibitor. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2068835/),h,11,203267,DB01197,Captopril
,23724654,mean residence time (MRT),"The pharmacokinetic results of erdosteine and its thiol-containing active metabolite showed that the area under curve (AUC) of the thiol-containing active metabolite was 6.2 times of that of erdosteine after a single oral dose of 600 mg erdosteine tables in 32 healthy volunteers, The mean residence time (MRT) of the thiol-containing active metabolite was (7.51 +/- 0.788) h, which provided a pharmacokinetic basis for the rational dosage regimen.",[Simultaneous determination of erdosteine and its active metabolite in human plasma by liquid chromatography-tandem mass spectrometry with pre-column derivatization]. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23724654/),h,7.51,204001,DB01197,Captopril
,1312853,AUC (0.72 h),"4. Values of AUC (0.72 h) for enalaprilat were 419 +/- 97 and 450 +/- 87 ng ml-1 h in the presence and absence of captopril, respectively.",The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312853/),[h·ng] / [ml],419,210329,DB01197,Captopril
,1312853,AUC (0.72 h),"4. Values of AUC (0.72 h) for enalaprilat were 419 +/- 97 and 450 +/- 87 ng ml-1 h in the presence and absence of captopril, respectively.",The effect of saturation of ACE binding sites on the pharmacokinetics of enalaprilat in man. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1312853/),[h·ng] / [ml],450,210330,DB01197,Captopril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [kcal·mol·mol],-7.6,212013,DB01197,Captopril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],-,212014,DB01197,Captopril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],8.8,212015,DB01197,Captopril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),[kcal] / [mol],8.0,212016,DB01197,Captopril
,30747089,free binding energy,"Niazicin-A, Niazimin-A and Niaziminin-B showed the estimated free binding energy of -7.6kcal/mol kcal/mol, -8.8kcal/mol and -8.0kcal/mol respectively with C-domain of ACE and -7.9kcal/mol, -8.5kcal/mol and -7.7kcal/mol respectively with N-domain of ACE.",Potential Angiotensin Converting Enzyme Inhibitors from Moringa oleifera. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30747089/),k,7.7,212017,DB01197,Captopril
,1926273,maximum concentration (Cmax),"For unchanged captopril, the maximum concentration (Cmax) was 350 +/- 184 ng/ml; the time to Cmax (Tmax), 1.6 +/- 0.4 h; elimination half-life (t1/2), 3.3 +/- 3.3 h; oral clearance (Clo), 1.1 +/- 0.4 L/h/kg.",The pharmacokinetics of captopril in infants with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926273/),[ng] / [ml],350,212565,DB01197,Captopril
,1926273,time to Cmax (Tmax),"For unchanged captopril, the maximum concentration (Cmax) was 350 +/- 184 ng/ml; the time to Cmax (Tmax), 1.6 +/- 0.4 h; elimination half-life (t1/2), 3.3 +/- 3.3 h; oral clearance (Clo), 1.1 +/- 0.4 L/h/kg.",The pharmacokinetics of captopril in infants with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926273/),h,1.6,212566,DB01197,Captopril
,1926273,elimination half-life (t1/2),"For unchanged captopril, the maximum concentration (Cmax) was 350 +/- 184 ng/ml; the time to Cmax (Tmax), 1.6 +/- 0.4 h; elimination half-life (t1/2), 3.3 +/- 3.3 h; oral clearance (Clo), 1.1 +/- 0.4 L/h/kg.",The pharmacokinetics of captopril in infants with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926273/),h,3.3,212567,DB01197,Captopril
,1926273,oral clearance (Clo),"For unchanged captopril, the maximum concentration (Cmax) was 350 +/- 184 ng/ml; the time to Cmax (Tmax), 1.6 +/- 0.4 h; elimination half-life (t1/2), 3.3 +/- 3.3 h; oral clearance (Clo), 1.1 +/- 0.4 L/h/kg.",The pharmacokinetics of captopril in infants with congestive heart failure. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926273/),[l] / [h·kg],1.1,212568,DB01197,Captopril
,1926273,Cmax,"For total captopril, Cmax was 1,088 +/- 621 ng/ml; Tmax, 2.7 +/- 1.1 h; t1/2, 3.4 +/- 1.0 h.",The pharmacokinetics of captopril in infants with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926273/),[ng] / [ml],"1,088",212569,DB01197,Captopril
,1926273,Tmax,"For total captopril, Cmax was 1,088 +/- 621 ng/ml; Tmax, 2.7 +/- 1.1 h; t1/2, 3.4 +/- 1.0 h.",The pharmacokinetics of captopril in infants with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926273/),h,2.7,212570,DB01197,Captopril
,1926273,t1/2,"For total captopril, Cmax was 1,088 +/- 621 ng/ml; Tmax, 2.7 +/- 1.1 h; t1/2, 3.4 +/- 1.0 h.",The pharmacokinetics of captopril in infants with congestive heart failure. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1926273/),h,3.4,212571,DB01197,Captopril
,7037265,volume of distribution (Vd),The average volume of distribution (Vd) was 0.2 l/kg for the central compartment and 2 l/kg for the elimination (beta) phase.,Captopril kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7037265/),[l] / [kg],0.2,217259,DB01197,Captopril
,7037265,volume of distribution (Vd),The average volume of distribution (Vd) was 0.2 l/kg for the central compartment and 2 l/kg for the elimination (beta) phase.,Captopril kinetics. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7037265/),[l] / [kg],2,217260,DB01197,Captopril
,7037265,Vd at steady-state,The Vd at steady-state was 0.7 l/kg.,Captopril kinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7037265/),[l] / [kg],0.7,217261,DB01197,Captopril
,7037265,total body clearance,The total body clearance of captopril averaged 0.8 l/kg/hr and the mean blood half-life during the beta phase was 1.9 hr.,Captopril kinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7037265/),[l] / [h·kg],0.8,217262,DB01197,Captopril
,7037265,blood half-life during the beta phase,The total body clearance of captopril averaged 0.8 l/kg/hr and the mean blood half-life during the beta phase was 1.9 hr.,Captopril kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7037265/),h,1.9,217263,DB01197,Captopril
,7037265,Absolute absorption,Absolute absorption of the radioactive oral dose was 71% and the absolute oral bioavailability of captopril was 62%.,Captopril kinetics. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7037265/),%,71,217264,DB01197,Captopril
,7037265,absolute oral bioavailability,Absolute absorption of the radioactive oral dose was 71% and the absolute oral bioavailability of captopril was 62%.,Captopril kinetics. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7037265/),%,62,217265,DB01197,Captopril
,8706772,tmax,"tmax after buffered sublingual administration of captopril, which ranged from 40-60 min (median = 40 min), was significantly shorter than after peroral administration (range 60-120 min, median = 90 min).",A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706772/),min,40-60,217740,DB01197,Captopril
,8706772,tmax,"tmax after buffered sublingual administration of captopril, which ranged from 40-60 min (median = 40 min), was significantly shorter than after peroral administration (range 60-120 min, median = 90 min).",A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706772/),min,40,217741,DB01197,Captopril
,8706772,tmax,"tmax after buffered sublingual administration of captopril, which ranged from 40-60 min (median = 40 min), was significantly shorter than after peroral administration (range 60-120 min, median = 90 min).",A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706772/),min,60-120,217742,DB01197,Captopril
,8706772,tmax,"tmax after buffered sublingual administration of captopril, which ranged from 40-60 min (median = 40 min), was significantly shorter than after peroral administration (range 60-120 min, median = 90 min).",A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706772/),min,90,217743,DB01197,Captopril
,8706772,Cmax,Cmax was slightly greater after buffered sublingual than after peroral administration with mean values of 108.2 vs.,A pharmacokinetic and pharmacodynamic evaluation of buffered sublingual captopril in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8706772/),,108.2,217744,DB01197,Captopril
,7028947,total body clearance (ClT),"The average total body clearance (ClT) and the renal clearance (ClR) of captopril, in milliliters per kilogram per hour, were 605 and 341 in the dog and 1135 and 944 in the monkey.",Pharmacokinetics of captopril in dogs and monkeys. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),,605,218767,DB01197,Captopril
,7028947,renal clearance (ClR),"The average total body clearance (ClT) and the renal clearance (ClR) of captopril, in milliliters per kilogram per hour, were 605 and 341 in the dog and 1135 and 944 in the monkey.",Pharmacokinetics of captopril in dogs and monkeys. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),,341,218768,DB01197,Captopril
,7028947,renal clearance (ClR),"The average total body clearance (ClT) and the renal clearance (ClR) of captopril, in milliliters per kilogram per hour, were 605 and 341 in the dog and 1135 and 944 in the monkey.",Pharmacokinetics of captopril in dogs and monkeys. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),,1135,218769,DB01197,Captopril
,7028947,renal clearance (ClR),"The average total body clearance (ClT) and the renal clearance (ClR) of captopril, in milliliters per kilogram per hour, were 605 and 341 in the dog and 1135 and 944 in the monkey.",Pharmacokinetics of captopril in dogs and monkeys. ,CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),,944,218770,DB01197,Captopril
,7028947,volume of distribution,The volume of distribution of captopril was higher in the monkey (3.6 liters/kg) than in the dog (2.6 liters/kg); the volume of the central compartment was about the same (0.5 liter/kg) for both species.,Pharmacokinetics of captopril in dogs and monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),[l] / [kg],3.6,218771,DB01197,Captopril
,7028947,volume of distribution,The volume of distribution of captopril was higher in the monkey (3.6 liters/kg) than in the dog (2.6 liters/kg); the volume of the central compartment was about the same (0.5 liter/kg) for both species.,Pharmacokinetics of captopril in dogs and monkeys. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),[l] / [kg],2.6,218772,DB01197,Captopril
,7028947,volume of the central compartment,The volume of distribution of captopril was higher in the monkey (3.6 liters/kg) than in the dog (2.6 liters/kg); the volume of the central compartment was about the same (0.5 liter/kg) for both species.,Pharmacokinetics of captopril in dogs and monkeys. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),[l] / [kg],0.5,218773,DB01197,Captopril
,7028947,terminal half-life,The terminal half-life value was slightly higher in the dog (2.8 hr) than in the monkey (2.2 hr).,Pharmacokinetics of captopril in dogs and monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),h,2.8,218774,DB01197,Captopril
,7028947,terminal half-life,The terminal half-life value was slightly higher in the dog (2.8 hr) than in the monkey (2.2 hr).,Pharmacokinetics of captopril in dogs and monkeys. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7028947/),h,2.2,218775,DB01197,Captopril
,6095854,peak plasma levels,Metabolism of the dimer to captopril has been shown after both oral and intravenous administration of the dimer (10 mg/kg) with peak plasma levels of captopril (154 ng/ml) occurring at 1 hr post dose.,Captopril disulfide conjugates may act as prodrugs: disposition of the disulfide dimer of captopril in the rat. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6095854/),[ng] / [ml],154,221119,DB01197,Captopril
,8879531,recoveries,The recoveries of captopril were 90%-98% for plasma.,HPLC determination of captopril in human plasma and its pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8879531/),%,90%-98,222705,DB01197,Captopril
,8879531,Tmax,"The results showed that the disposition of captopril was conformed to a two-compartment open model with Tmax = 0.56 h, Cmax = 266.5 ng/mL and AUC(zero)-infinity = 380.3 ng.h/mL.",HPLC determination of captopril in human plasma and its pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8879531/),h,0.56,222706,DB01197,Captopril
,8879531,Cmax,"The results showed that the disposition of captopril was conformed to a two-compartment open model with Tmax = 0.56 h, Cmax = 266.5 ng/mL and AUC(zero)-infinity = 380.3 ng.h/mL.",HPLC determination of captopril in human plasma and its pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8879531/),[ng] / [ml],266.5,222707,DB01197,Captopril
,8879531,AUC(zero)-infinity,"The results showed that the disposition of captopril was conformed to a two-compartment open model with Tmax = 0.56 h, Cmax = 266.5 ng/mL and AUC(zero)-infinity = 380.3 ng.h/mL.",HPLC determination of captopril in human plasma and its pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8879531/),[h·ng] / [ml],380.3,222708,DB01197,Captopril
,2203579,Absorption,"Absorption of the active diacids is generally poor, and moderate (typically 30 to 70%) for the prodrugs.",Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,30 to 70,223514,DB01197,Captopril
,2203579,bioavailability,The bioavailability of lisinopril is about 25%.,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,25,223515,DB01197,Captopril
,2203579,Half-lives of accumulation,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),h,12,223516,DB01197,Captopril
,2203579,protein binding,Half-lives of accumulation are of the order of 12 hours; protein binding varies from little (lisinopril) to 90% (benazeprilat).,Clinical pharmacokinetics of the newer ACE inhibitors. A review. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2203579/),%,90,223517,DB01197,Captopril
,8910853,detection limit,"The antibodies were used to develop an enzyme-linked immunosorbent assay (ELISA) with a detection limit of 0.3 ng mL-1 and intra- and inter-assay coefficients of variation of 7 and 12%, respectively.",Determination of captopril in human blood by an enzyme-linked immunosorbent assay. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8910853/),[ng] / [ml],0.3,225475,DB01197,Captopril
,2994938,elimination half-life,The elimination half-life for unchanged captopril is about 1.7 hours and is markedly increased in the presence of renal insufficiency.,Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2994938/),h,1.7,238933,DB01197,Captopril
,2994938,tmax,"After the oral administration of enalapril, the tmax for enalapril is one hour, but for enalaprilat it is 4 hours.",Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2994938/),h,one,238934,DB01197,Captopril
,2994938,tmax,"After the oral administration of enalapril, the tmax for enalapril is one hour, but for enalaprilat it is 4 hours.",Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors. A review. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2994938/),h,4,238935,DB01197,Captopril
,8830975,ClTB,ClTB was estimated to be 1.42 +/- 0.33 L h-1 kg(-1); t1/2 was 0.44 +/- 0.08 h; Vdss was calculated to be 0.64 +/- 0.13 L kg(-1); t1/2 and AUC0-infinity was estimated to be 145 +/- 27 ng h mL(-1).,Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830975/),[l] / [h·kg],1.42,248965,DB01197,Captopril
,8830975,t1/2,ClTB was estimated to be 1.42 +/- 0.33 L h-1 kg(-1); t1/2 was 0.44 +/- 0.08 h; Vdss was calculated to be 0.64 +/- 0.13 L kg(-1); t1/2 and AUC0-infinity was estimated to be 145 +/- 27 ng h mL(-1).,Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830975/),h,0.44,248966,DB01197,Captopril
,8830975,Vdss,ClTB was estimated to be 1.42 +/- 0.33 L h-1 kg(-1); t1/2 was 0.44 +/- 0.08 h; Vdss was calculated to be 0.64 +/- 0.13 L kg(-1); t1/2 and AUC0-infinity was estimated to be 145 +/- 27 ng h mL(-1).,Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830975/),[l] / [kg],0.64,248967,DB01197,Captopril
,8830975,AUC0-infinity,ClTB was estimated to be 1.42 +/- 0.33 L h-1 kg(-1); t1/2 was 0.44 +/- 0.08 h; Vdss was calculated to be 0.64 +/- 0.13 L kg(-1); t1/2 and AUC0-infinity was estimated to be 145 +/- 27 ng h mL(-1).,Pharmacokinetic-pharmacodynamic modelling for captopril in healthy anaesthetized piglets. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8830975/),[h·ng] / [ml],145,248968,DB01197,Captopril
,19559901,flow rate,The flow rate was 1 mL/min at the column temperature of 30 degrees C.,Determination of free captopril in human plasma by liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19559901/),[ml] / [min],1,252038,DB01197,Captopril
,19559901,retention time,"In these chromatographic conditions, the retention time was 4.4 min for captopril derivative.",Determination of free captopril in human plasma by liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19559901/),min,4.4,252039,DB01197,Captopril
,19559901,recovery,The mean recovery of the analyte was 99%.,Determination of free captopril in human plasma by liquid chromatography with mass spectrometry detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19559901/),%,99,252040,DB01197,Captopril
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],6404,255254,DB01197,Captopril
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],3105,255255,DB01197,Captopril
,7641363,area under the plasma active renin versus time curve (0 to 24 hours),"After combined losartan-captopril administration, the area under the plasma active renin versus time curve (0 to 24 hours) was significantly increased when compared with either losartan or captopril alone (6404 +/- 2961 pg.h.mL-1 versus 3105 +/- 1461 pg.h.mL-1 versus 2092 +/- 867 pg.h.mL-1, respectively, P < .05).",Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7641363/),[h·pg] / [ml],2092,255256,DB01197,Captopril
,7898090,half-life,"We showed that single oral doses of cilazapril 4 mg, captopril 25 mg, or enalapril 10 mg shifted the angiotensin I dose-effect curve to the right and determined a pharmacologic half-life of about 4 h for cilazapril.",Review of studies on the clinical pharmacodynamics of cilazapril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),h,4,262739,DB01197,Captopril
,7898090,apparent Ki dose,The dose representing 50% inhibition of ACE activity (apparent Ki dose) was about 0.6 mg 3 h after cilazapril administration.,Review of studies on the clinical pharmacodynamics of cilazapril. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7898090/),mg,0.6,262740,DB01197,Captopril
,23071948,half-life,"Conventional drug delivery system of captopril is inappropriate for the delivery of drug, as they cannot be administered just before the symptoms are worsened, because during this time the patients are asleep, bedtime dosing of captopril will not provide a therapeutic plasma drug concentration at the early hours of morning because of poor pharmacokinetic profile and shorter half-life of 1.9 hours.",Development and characterization of chronomodulated drug delivery system of captopril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23071948/),h,1.9,263223,DB01197,Captopril
,23071948,lag time,"Thus, this study attempts to design and evaluate a chronomodulated pulsatile drug delivery system of captopril which was aimed to release the drug after a lag time of 6 hours.",Development and characterization of chronomodulated drug delivery system of captopril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23071948/),h,6,263224,DB01197,Captopril
,23071948,lag time,The system was found to be satisfactory in terms of release of the drug after the lag time of 6 hours.,Development and characterization of chronomodulated drug delivery system of captopril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23071948/),h,6,263225,DB01197,Captopril
,2148447,half-life,The calculated half-life of captopril was 4.4 h.,Uneventful self poisoning with a very high dose of captopril. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2148447/),h,4.4,268969,DB01197,Captopril
,2148447,amount of absorbed,The calculated amount of absorbed captopril was approximately 5400 mg.,Uneventful self poisoning with a very high dose of captopril. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2148447/),mg,540,268970,DB01197,Captopril
,8849263,half-life,Captopril increased the cefdinir half-life from 0.62 +/- 0.17 to 2.92 +/- 0.95 h.,Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8849263/),h,0.62,269692,DB01197,Captopril
,8849263,half-life,Captopril increased the cefdinir half-life from 0.62 +/- 0.17 to 2.92 +/- 0.95 h.,Pharmacokinetic interaction between cefdinir and two angiotensin-converting enzyme inhibitors in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8849263/),h,2.92,269693,DB01197,Captopril
